SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001576885-23-000037
Filing Date
2023-06-07
Accepted
2023-06-07 17:45:31
Documents
4
Period of Report
2023-06-06

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1686174319.html 4  
1 FORM 4 wk-form4_1686174319.xml 4 3938
2 EX-24.1 acumen-section16limitedp.htm EX-24.1 3963
3 acumen-section16limitedp001.jpg GRAPHIC 195024
4 acumen-section16limitedp002.jpg GRAPHIC 36559
  Complete submission text file 0001576885-23-000037.txt   328456
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Issuer) CIK: 0001576885 (see all company filings)

IRS No.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O ACUMEN PHARMACEUTICALS, INC. 427 PARK STREET CHARLOTTESVILLE VA 22902
Business Address
Stalfort John A III (Reporting) CIK: 0001709418 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40551 | Film No.: 231000085